Chourey Tejaswita, Khan Yasmee, Pakhare Abhijit P, Singhai Abhishek, Parashar Rachna, Joshi Rajnish, Meena Mahadev
Internal Medicine, All India Institute of Medical Sciences (AIIMS) Bhopal, Bhopal, IND.
Community and Family Medicine, All India Institute of Medical Sciences (AIIMS) Bhopal, Bhopal, IND.
Cureus. 2025 May 12;17(5):e83948. doi: 10.7759/cureus.83948. eCollection 2025 May.
The screening for thyroid function abnormalities in asymptomatic individuals remains a topic of debate. The impact of subclinical hypothyroidism (SCH) on glucose metabolism has been less extensively researched. Our study aimed to assess the feasibility of thyroid-stimulating hormone (TSH)-based screening and evaluate the prevalence of SCH among individuals with impaired glucose tolerance (IGT) in a community-based setting. Methodology: We performed a longitudinal study in individuals with IGT by measuring clinical parameters and TSH at baseline and follow-up measurements at 6 and 12 months.
We included 148 participants with IGT. The baseline mean HbA1c of the participants was 6.0% ± 0.2%, and the TSH level was 3.2 ± 2.1 µIU/mL. In the study, we found that 18 (12.2%) individuals with IGT had baseline TSH values in the SCH range (TSH 5-10 µIU/mL). Individuals with IGT who also had a TSH abnormality had significantly lower HbA1c levels as compared to those who were euthyroid (5.9% ± 0.2% vs. 6.1% ± 0.2%, < 0.008). Other measurements were similar between the two groups. There was a significant decline in mean HbA1c levels on follow-up (baseline HbA1c 6.1% ± 0.2% vs. follow-up HbA1c 5.4% ± 0.7%; < 0.001). One year later, 14 individuals (87.5%) with SCH reverted to normal TSH levels without specific thyroxine therapy, while 17 individuals (15.8%) who were initially euthyroid developed TSH elevations into the SCH range, suggesting dynamic fluctuations in TSH levels among individuals. There was, however, no change in mean TSH levels on follow-up (baseline 3.2 ± 1.8 µIU/mL vs. follow-up 2.9 ± 2.3 µIU/mL; = 0.22). The overall prevalence of SCH at baseline and follow-up was similar (16, 13.2%, vs. 18, 14.9%; = 0.855).
The study highlights that SCH is a transient condition among individuals with IGT. The majority of these individuals reverted to normal thyroid function after one year without requiring thyroid hormone therapy, underscoring the unstable nature of SCH.
对无症状个体进行甲状腺功能异常筛查仍是一个有争议的话题。亚临床甲状腺功能减退(SCH)对糖代谢的影响研究较少。我们的研究旨在评估基于促甲状腺激素(TSH)筛查的可行性,并评估社区糖耐量受损(IGT)个体中SCH的患病率。
我们对IGT个体进行了一项纵向研究,在基线时测量临床参数和TSH,并在6个月和12个月时进行随访测量。
我们纳入了148名IGT参与者。参与者的基线平均糖化血红蛋白(HbA1c)为6.0%±0.2%,TSH水平为3.2±2.1μIU/mL。在研究中,我们发现18名(12.2%)IGT个体的基线TSH值处于SCH范围内(TSH 5 - 10μIU/mL)。与甲状腺功能正常的IGT个体相比,TSH异常的IGT个体的HbA1c水平显著更低(5.9%±0.2%对6.1%±0.2%,<0.008)。两组之间的其他测量结果相似。随访时平均HbA1c水平有显著下降(基线HbA1c 6.1%±0.2%对随访HbA1c 5.4%±0.7%;<0.001)。一年后,14名(87.5%)SCH个体在未接受特定甲状腺素治疗的情况下TSH水平恢复正常,而17名(15.8%)最初甲状腺功能正常的个体TSH升高至SCH范围,表明个体间TSH水平存在动态波动。然而,随访时平均TSH水平无变化(基线3.2±1.8μIU/mL对随访2.9±2.3μIU/mL;=0.22)。基线和随访时SCH的总体患病率相似(16例,13.2%,对18例,14.9%;=0.855)。
该研究强调SCH在IGT个体中是一种短暂的情况。这些个体中的大多数在一年后无需甲状腺激素治疗即可恢复正常甲状腺功能,突出了SCH的不稳定性质。